In this episode, Martin examines a deal between OpenAI and AMD that he views as unusually suspicious, exploring its possible implications for the market. He also provides detailed analysis of Ambarella and Monopar Therapeutics, outlining the key factors shaping his outlook on both stocks.

In this episode, Martin presents a special “Best Of” compilation, revisiting key moments, insights, and lessons from previous streams. He highlights major themes and takeaways to help viewers prepare for what’s ahead in the market.

In this episode, Martin discusses why he believes shorting GPU providers could be the next major opportunity in the market and explores the factors driving that view. He also announces a competition with prizes for the best-performing Godel traders.

In this episode, Martin walks through the history of EA’s notable takeover and the broader lessons it offers for investors. He also looks at recent positive news from Rigetti and analyzes why it failed to significantly move the stock.

In this episode, Martin shares what he considers the easiest short opportunity in the market right now — and clarifies that he’s not referring to IonQ. He also discusses notable news from IBM and examines his view on Soundhound stock.

In this episode, Martin shares his view that HIMS is evolving into a binary investment and outlines his prediction for the stock’s future. He also discusses the controversy surrounding Tylenol and autism, and examines the recent drop in Opendoor’s stock.

In this episode, Martin reviews the outcome of his short position in Joby and the lessons taken from the trade. He also discusses the implications of a deal between NVIDIA and OpenAI, and highlights why a BlackRock investor has taken a bullish stance on Quantum.

In this episode, Martin talks about how his Opendoor position was undone and analyzes the renewed activity around Quantum. He also explains how he is approaching options in the current market environment.

In this episode, Martin details how he lost millions while shorting Quantum and explains the sequence of events that led to the trade. He also discusses the broader market context and outlines how these developments may affect Opendoor’s stock going forward.

OPEN’s CEO is dodging calls, Atyr’s gains have vanished, and quantum investing is making noise again. Here’s what went down:
– Ghosted by OPEN’s CEO
– Atyr’s biotech rollercoaster
– Quantum investing buzz